Wang Guochun

[Expert Profile] Wang Guochun, Chief Physician, Professor, Doctoral Supervisor, is an authoritative expert in inflammatory myopathy in China, working in the Department of Rheumatology, China-Japan Friendship Hospital. He has long been dedicated to the clinical diagnosis, treatment, and scientific research of polymyositis, dermatomyositis, and rheumatic diseases complicated with interstitial lung disease, and is an important leading figure in inflammatory myopathy research in China.

[Education & Career] Professor Wang Guochun graduated from a renowned medical university, completed systematic clinical training at China-Japan Friendship Hospital, and further studied at famous international rheumatology centers, systematically mastering cutting-edge diagnosis and treatment techniques for inflammatory myopathy and interstitial lung disease. He has long served as Director of the Rheumatology Department at China-Japan Friendship Hospital, holding academic positions including standing committee member of the Rheumatology Branch of the Chinese Medical Association. He has presided over grants from the National Natural Science Foundation of China and the National Key R&D Program, and is a senior expert in the field of inflammatory myopathy.

[Areas of Expertise] Professor Wang specializes in the diagnosis and treatment of polymyositis, dermatomyositis, and various inflammatory myopathies, with particularly extensive experience in early identification and comprehensive treatment of inflammatory myopathy complicated with interstitial lung disease (ILD) — a highly lethal complex condition. He is proficient in muscle biopsy pathology interpretation, myositis-specific antibody testing interpretation, and individualized application of immunosuppressive therapy and biologics. He excels at managing critically ill patients with "muscle weakness accompanied by dyspnea," helping numerous myopathy patients control their conditions and preserve respiratory function.

[Academic Achievements & Industry Contributions] Professor Wang has led the establishment of a Chinese inflammatory myopathy clinical cohort, systematically studying the clinical features, antibody profiles, and prognostic factors of patients with myositis combined with interstitial lung disease, with findings published in authoritative domestic and international journals, providing important basis for precise subtyping and individualized treatment of inflammatory myopathy. He has participated in the development of Chinese diagnosis and treatment guidelines and expert consensus statements for inflammatory myopathy and connective tissue disease-related interstitial lung disease, actively promoted the clinical application of myositis-specific antibody testing, and led multi-center research, significantly improving the overall diagnosis and treatment level of inflammatory myopathy and its complications in China.

[Clinical Practice & Outstanding Contributions] For decades on the clinical front lines, Professor Wang has treated tens of thousands of patients with polymyositis, dermatomyositis, and combined interstitial lung disease, including many critically ill difficult cases. Leading his team, he has established a multidisciplinary collaborative treatment system for inflammatory myopathy, successfully treating numerous patients on the "verge of respiratory failure" with myositis combined with interstitial lung disease, saving the lives of many young patients. He has been repeatedly recognized as an outstanding physician and outstanding discipline leader, and is deeply trusted by patients and respected by peers alike. He is an outstanding expert in the field of inflammatory myopathy prevention and treatment in China.

[Honors & Reputation] Professor Wang Guochun serves as Director of the Rheumatology Department at China-Japan Friendship Hospital and a standing committee member of the Rheumatology Branch of the Chinese Medical Association, among other academic positions. He has presided over national-level projects including key grants from the National Natural Science Foundation of China, and is an important expert in the field of rheumatology in China. He has profound expertise in the diagnosis and treatment of polymyositis, dermatomyositis, and rheumatic diseases complicated with interstitial lung disease. He has led the establishment of a multidisciplinary diagnosis and treatment system for myositis and interstitial lung disease, systematically conducted research on dermatomyositis-related interstitial lung disease, promoted standardized application of myositis antibody testing, and has research findings published in international authoritative journals. For decades on the clinical front lines, he has helped numerous critically ill patients with interstitial lung disease combined with rheumatic disease turn the corner, and is deeply trusted by patients and respected by peers alike.